Faculté des Sciences de La Motricité, Université Catholique de Louvain, Louvain-La-Neuve, Belgium.
Institut de Recherche Expérimentale et Clinique, Neuro Musculo Skeletal Lab, Université Catholique de Louvain, Secteur des Sciences de La Santé, Brussels, Belgium.
J Man Manip Ther. 2021 Apr;29(2):73-82. doi: 10.1080/10669817.2020.1805690. Epub 2020 Aug 18.
This study compared the modification of musculoarticular stiffness (MAS) and clinical outcomes after mobilization with movement (MWM) on the inferior tibiofibular joint and a placebo MWM. Moreover, injured and non-injured ankle MAS were compared after MWM therapy.
A single-blinded randomized trial was conducted on 75 participants (mean age: 22.3 ± 2.17 years) with chronic self-reported asymmetric perception of ankle dorsiflexion stiffness. Participants were allocated to one of three groups: inferior tibiofibular MWM (ITFMWM), placebo and non-injured. Sinusoidal oscillation methods were used for experimental quantification of the MAS and clinical outcomes were assessed using the weight-bearing lunge test (WBLT), pain and stiffness perception. Three assessments were made: one pre-treatment (T0), one after the manual technique (T1) and one after taping (T2).
Two-way ANOVA showed no significant differences between the groups and no interaction effect for the outcome measures. However, a significant difference for the time effect (T0-T1-T2) was found in the three groups for WBLT dorsiflexion range of motion (p < 0.001, Cohen's d = 0.21) and stiffness perception (p < 0.001, Cohen's d = 0.54) but the minimal clinically important differences were not reached for either value.
The results could not support that a single session of ITFMWM modifies MAS or the clinical outcomes compared to placebo treatment. Furthermore, injured MAS does not differ from non-injured MAS in chronic ankle dorsiflexion stiffness. Further studies should assess subjects' responsiveness concerning the Mulligan concept and focus on a medium- to long-term follow-up.
本研究比较了在下胫腓关节进行动觉松动术(MWM)与安慰剂 MWM 对肌骨关节僵硬(MAS)的改善作用和临床疗效。此外,还比较了 MWM 治疗后受伤和未受伤踝关节的 MAS。
一项单盲随机临床试验纳入了 75 名慢性踝关节背屈僵硬感不对称的自我报告患者(平均年龄 22.3 ± 2.17 岁)。参与者被随机分配到下胫腓 MWM(ITFMWM)、安慰剂和未受伤三组。采用正弦摆动法对 MAS 进行实验量化,并用负重下蹲试验(WBLT)、疼痛和僵硬感知评估临床疗效。进行了三次评估:治疗前(T0)、手法治疗后(T1)和贴扎后(T2)。
两因素方差分析显示,各组之间的结局测量值无显著差异,也无交互效应。然而,三组在 WBLT 背屈活动范围(p<0.001,Cohen's d=0.21)和僵硬感知(p<0.001,Cohen's d=0.54)的时间效应(T0-T1-T2)方面存在显著差异,但两种情况下均未达到最小临床重要差异。
结果不能支持单次 ITFMWM 治疗与安慰剂治疗相比能改善 MAS 或临床疗效。此外,慢性踝关节背屈僵硬的受伤 MAS 与未受伤 MAS 无差异。进一步的研究应评估患者对 Mulligan 概念的反应性,并关注中至长期随访。